No Data
No Data
AbCellera Expands Discovery Partnership With AbbVie
Express News | Abcellera Biologics: To Get Upfront, Research Payments, Is Eligible to Get Downstream Milestone Payments & Tiered Royalty Payments on Net Sale
Express News | Abcellera Expands Collaboration With Abbvie to Develop Novel T-Cell Engagers for Oncology
AbCellera Expands Collaboration With AbbVie to Develop Novel T-Cell Engagers for Oncology
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $4
KeyBanc Cuts Price Target on AbCellera Biologics to $4 From $5, Keeps Overweight Rating